Teva Pharmaceutical Industries Limited Announces Launch of Generic Protonix(R) Tablets, 20 mg and 40 mg

JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) announced today that it has commercially launched Pantoprazole Sodium Delayed Release (DR) Tablets, 20 mg and 40 mg, which are AB-rated to Wyeth’s erosive GERD treatment Protonix® DR Tablets. The brand product had annual sales of approximately $2.5 billion in the United States for the twelve months ended September 30, 2007, based on IMS sales data.

MORE ON THIS TOPIC